PharmaShots | Incisive News in 3 Shots

Subscribe Now

Novartis

Novartis and Medicines for Malaria Venture Seeks to Advance Ganaplacide/Lumefantrine-SDF Combination Therapy in P-III Study for Malaria

Novartis and Medicines for Malaria Venture Seeks to Advance Ganaplacide/Lumefantrine-SDF Combination Therapy in P-III Study for Ma...

November 24, 2022

Novartis’ Cosentyx (secukinumab) Receives the MHRA’s Marketing Authorisation for Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis

Novartis’ Cosentyx (secukinumab) Receives the MHRA’s Marketing Authorisation for Enthesitis-Related Arthritis and Juvenile Psoriat...

November 10, 2022

Novartis Reports P-III (APPLY-PNH) Trial Results of Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports P-III (APPLY-PNH) Trial Results of Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

October 25, 2022

Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

September 9, 2022

PharmaShots Weekly Snapshots (September 05 - 09, 2022)

PharmaShots Weekly Snapshots (September 05 - 09, 2022)

September 9, 2022

Novartis’ Scemblix (asciminib) Receives EC’s Approval for the Treatment of Chronic Myeloid Leukemia

Novartis’ Scemblix (asciminib) Receives EC’s Approval for the Treatment of Chronic Myeloid Leukemia

August 29, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us